Premium
Combined Effects of Streptozotocin and Doxorubicin on Cardiac Function in Rats
Author(s) -
Greufe Stephanie Erin,
Gibson Noah M,
Hydock David S,
Schneider Carole M,
Hayward Reid
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.701.8
Subject(s) - streptozotocin , diabetes mellitus , medicine , doxorubicin , cardiac function curve , in vivo , blood pressure , saline , endocrinology , cancer , cardiac dysfunction , ex vivo , pharmacology , heart failure , chemotherapy , biology , microbiology and biotechnology
Diabetes is a metabolic disorder that affects over 25 million Americans. Large epidemiological studies have shown that individuals with diabetes are at increased risk of many types of cancer; including those often treated with the cardiotoxic anticancer drug doxorubicin (DOX). PURPOSE To examine the combined effects of streptozotocin (STZ) ‐induced diabetes and DOX on cardiac function. METHODS Twenty four rats were given an injection of STZ in order to induce diabetes. Three days following STZ injection, diabetes was confirmed in 21 rats. Blood glucose (BG) was measured each week for 10 weeks at which time 7 rats received a DOX (10 mg/kg) injection and the remaining received a saline (SAL) injection. Cardiac function was assessed both in vivo and ex vivo 5 days post injections. Controls of identical age were used in the statistical analysis. RESULTS Fractional shortening, left ventricular developed pressure and end systolic pressure all decreased significantly (p<.05) in STZ animals. STZ + DOX animals showed additional declines (p<.05) compared to STZ alone and DOX alone. CONCLUSION Both STZ and DOX independently induced cardiac dysfunction and this dysfunction was exacerbated when these two were combined. This suggests that diabetes may be a complicating factor when considering DOX‐induced cardiac dysfunction in cancer patients undergoing treatment with this chemotherapeutic agent.